In this webinar, experts discuss new research in bladder cancer, kidney cancer, prostate cancer, and testicular cancer presented at the 2022 ASCO Annual Meeting and the 2022 Genitourinary Cancers Symposium.
Sharie Lisowski shares how she and her husband reacted to his prostate cancer diagnosis and how they worked together to help him choose the best treatment plan for him.
At-home DNA tests have become increasingly popular in recent years. But are they actually helpful for detecting cancer risk? In this post, learn about at-home DNA tests for cancer risk and why it’s always best to get genetic screening done through your health care provider.
Predicting Metastatic Prostate Cancer Risk in a Diverse Population: Research from the 2022 Genitourinary Cancers Symposium
Research from ASCO’s 2022 Genitourinary Cancers Symposium features a study on predicting the risk of developing and dying from metastatic prostate cancer in a diverse population.
In this “Voices on Cancer” post, prostate cancer survivor James E. Williams, Jr., shares how his experience with prostate cancer led him to understand the importance of patient advocacy and inspired him to get involved in bringing awareness to the disease.
In this webinar, experts discuss new research in genitourinary cancers presented at the 2021 ASCO Annual Meeting and the 2021 Genitourinary Cancers Symposium that highlighted advances in treating prostate, bladder, kidney, and testicular cancers.
2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Kidney Cancer, and Nasopharyngeal Cancer
The ASCO Annual Meeting begins on June 4, and here is some of the notable research that will be presented. Topics include combined immunotherapy for esophageal cancer, targeted radiation for mCRPC, olaparib for HER2-negative breast cancer, adjuvant chemotherapy for cervical cancer, pembrolizumab for kidney cancer, and toripalimab for nasopharyngeal cancer.
In the latest podcast in the “Clinical Trials in Genitourinary Cancers” series, experts discuss 3 clinical trials testing new treatment options for kidney cancer, muscle-invasive bladder cancer, and metastatic castration-sensitive prostate cancer.
2021 ASCO Annual Meeting: Immunotherapy for Melanoma and Non-Small Cell Lung Cancer, PSA Screening for Prostate Cancer in Young Black Men, HPV Vaccination and Cancer Rates, and Effects of Medicaid Income Eligibility Limits on Cancer Survival Rates
Read early research highlights just released for the 2021 ASCO Annual Meeting. Topics include immunotherapy for melanoma and non-small cell lung cancer, PSA screening for prostate cancer, HPV vaccination, and Medicaid income eligibility limits.
Reunión anual de la ASCO 2021: Inmunoterapia para el melanoma y el NSCLC, la detección del PSA en hombres jóvenes de raza negra, la vacunación contra el VPH y las tasas de cáncer, y los efectos de los límites de elegibilidad de Medicaid sobre el cáncer
Lea los puntos destacados de la investigación temprana que acaban de publicar para la reunión anual de la American Society of Clinical Oncology (Sociedad Americana de Oncología Clínica) de 2021. Los temas incluyen la inmunoterapia para el melanoma y el cáncer de pulmón de no microcítico (NSCLC, por sus siglas en inglés), la detección del antígeno prostático específico (PSA, por sus siglas en inglés) para el cáncer de próstata, la vacunación contra el VPH y los límites de elegibilidad de los ingresos de Medicaid.